Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharma to launch MS treatment in Germany after regulatory approval

GW Pharma to launch MS treatment in Germany after regulatory approval

GW Pharmaceuticals (LON:GWP) is prepared to launch its Sativex treatment for multiple sclerosis in Germany this July after the country’s health authorities granted regulatory approval for the treatment. Sativex is already available for MS patients in the UK and in Spain.

The medicine is a first-in-class ‘endocannabinoid’ (cannabis-based) system modulator for the treatment of spasticity in MS. It is delivered by a spray that can be delivered into the mouth either onto the inside of the cheek or under the tongue.

Spasticity (also known as muscle stiffness) has a negative impact on patients’ daily lives as it reduces their capacity to carry out everyday activities such as walking and keeping upright, as well as having an impact on their general mobility, bladder function and quality of sleep.

According to GW Pharma, around half of people with MS do not manage to find relief from these symptoms with currently-available treatments.

The firm says that evidence generated from clinical trials shows that Sativex has a positive impact on spasticity in MS, while alleviating associated symptoms.

“Having recently successfully launched Sativex in Spain, we are very pleased to have now received regulatory approval in Germany,” said Justin Gover, GW Pharma’s managing director. “Germany has the largest MS population in Europe and we look forward to offering people with MS in Germany the opportunity to benefit from Sativex as a new first in class treatment to treat their spasticity.”

The approval of the medicine in Germany follows the successful completion in March this March of the European Mutual Recognition Procedure (MRP) with all six countries involved – Germany, Denmark, Sweden, Italy, the Czech Republic and Austria – recommending approval. GW Pharma plans to make a further MRP submission later this year in order to expand the approval of Sativex.

GW Pharma’s share price was up 0.2 per cent at midday today at 120.25 pence.

 

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
Summit
January 25 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said
1518096073_biotechLatest.jpg
February 08 2018
The subsector in which Abezena is active in (monoclonal antibody and conjugated monoclonal antibodies) could expand to US$180bn, Peel Hunt’s research suggests

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use